Antisense compounds targeting apolipoprotein E receptor 2
AssigneesIonis Pharmaceuticals, Inc., Rosalind Franklin University of Medicine and Science
InventorsFrank Rigo, Michelle L. Hastings
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds comprising oligonucleotides complementary to an LRP8 transcript. Certain such compounds are useful for hybridizing to an LRP8 transcript, including but not limited, to an LRP8 transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the LRP8 transcript. In certain embodiments, such hybridization results in an increase in inclusion of exon 19 in the LRP8 mRNA transcript. In certain embodiments, such compounds are used to treat Alzheimer's Disease.
Claims19
A compound comprising a modified oligonucleotide consisting of 8 to 30 linked nucleosides complementary to a target region of an LRP8 transcript, wherein the modified oligonucleotide has a nucleobase sequence comprising at least 8 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs:
- 3-30.
Dependencies are inferred from the claim text.